Leqembi 100 mg/mL concentrate for solution for infusion
*Company:
Eisai LtdStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
File name
Eisai_Lec_Patient Card_Jan 2026.pdf
Reasons for updating
- Add New Doc
File name
Eisai_Lec_HCP guide_Checklist _Jan 2026.pdf
Reasons for updating
- Add New Doc
File name
Eisai_Lec_Patient Card_v3.0_20.01.2026.pdf
Reasons for updating
- Add New Doc
File name
Eisai_Lec_HCP guide_Checklist _v3.0_20.01.2026.pdf
Reasons for updating
- Add New Doc
Updated on 10 October 2025
File name
ROI Leqembi PIL Sept 2025.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - what the product contains
Updated on 10 October 2025
File name
ROI Leqembi SmPC Sept 2025.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to restricted prescription (C)
Updated on 08 September 2025
File name
ROI Leqembi SmPC June 2025.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 08 September 2025
File name
ROI Leqembi PIL April 2025.pdf
Reasons for updating
- New PIL for new product
Eisai Ltd
Address:
EMEA Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UKMedical Information E-mail:
EUMedInfo@eisai.netTelephone:
+44 (0)208 600 1400Website:
https://www.eisai.eu